ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Active Pharmaceutical Ingredients (API) CDMO Market Research Report 2025
Published Date: April 2025
|
Report Code: QYRE-Auto-21Q13231
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Active Pharmaceutical Ingredients API CDMO Market Research Report 2023
BUY CHAPTERS

Global Active Pharmaceutical Ingredients (API) CDMO Market Research Report 2025

Code: QYRE-Auto-21Q13231
Report
April 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO

Active Pharmaceutical Ingredients (API) CDMO Market Size

The global market for Active Pharmaceutical Ingredients (API) CDMO was valued at US$ 62590 million in the year 2024 and is projected to reach a revised size of US$ 107850 million by 2031, growing at a CAGR of 8.2% during the forecast period.

Active Pharmaceutical Ingredients (API) CDMO Market

Active Pharmaceutical Ingredients (API) CDMO Market Major Factors

 
The Active Pharmaceutical Ingredients (API) and Contract Development and Manufacturing Organization (CDMO) market is driven by the rising demand for outsourced pharmaceutical development and production. APIs form the backbone of drug formulations, and outsourcing their development allows pharmaceutical companies to focus on innovation while reducing operational costs. CDMOs provide scalability, regulatory expertise, and advanced manufacturing capabilities, meeting the growing needs of global drug manufacturers. Increasing complexity of biologics and personalized medicine further fuels demand for specialized CDMO services. Additionally, regulatory compliance pressures make outsourcing a strategic choice, ensuring consistent quality and faster time-to-market for pharmaceutical products.

Active Pharmaceutical Ingredients (API) CDMO Market Trends

A key trend is the increasing focus on biologics and biosimilars, where specialized API development and manufacturing expertise is essential. CDMOs are expanding capabilities in biologics to meet pharmaceutical companies’ demand for cutting-edge therapies, reflecting the market’s evolution toward advanced drug modalities.

Another trend is the adoption of flexible manufacturing systems and modular facilities by CDMOs. This enables faster scaling of production while maintaining compliance with stringent quality standards. The shift supports the pharmaceutical industry’s need for agility in response to changing market demands.

The globalization of drug development is also shaping trends, with pharmaceutical companies leveraging CDMOs in diverse regions for cost efficiency and supply chain resilience. This distributed model reduces dependency on a single geography, ensuring uninterrupted drug supply during global disruptions.

Active Pharmaceutical Ingredients (API) CDMO Market Share

The market is led by large CDMOs with strong regulatory expertise and global presence, enabling them to support multinational pharmaceutical companies. Firms offering end-to-end services from API development to final dosage manufacturing secure larger market share.

Regionally, Asia-Pacific dominates due to cost advantages and manufacturing capacity. North America holds strong share driven by innovation in biologics, while Europe remains influential with stringent regulatory expertise. This balance highlights how regional strengths shape the competitive landscape for APIs and CDMOs.

Market Segmentation

Scope of Active Pharmaceutical Ingredients (API) CDMO Market Report

Report Metric Details
Report Name Active Pharmaceutical Ingredients (API) CDMO Market
Accounted market size in year US$ 62590 million
Forecasted market size in 2031 US$ 107850 million
CAGR 8.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Clinical
  • Commercial
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Recipharm, Cambrex Corporation, Patheon (Thermo Fisher Scientific), CordenPharma, Lonza, Siegfried, Catalent, Boehringer Ingelheim, Piramal Group, AbbVie, SGS Quay Pharmaceuticals, Aenova Group, Curia, Sterling Pharma Solutions, Eurofins CDMO
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Active Pharmaceutical Ingredients (API) CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Active Pharmaceutical Ingredients (API) CDMO Market growing?

Ans: The Active Pharmaceutical Ingredients (API) CDMO Market witnessing a CAGR of 8.2% during the forecast period 2025-2031.

What is the Active Pharmaceutical Ingredients (API) CDMO Market size in 2031?

Ans: The Active Pharmaceutical Ingredients (API) CDMO Market size in 2031 will be US$ 107850 million.

Who are the main players in the Active Pharmaceutical Ingredients (API) CDMO Market report?

Ans: The main players in the Active Pharmaceutical Ingredients (API) CDMO Market are Recipharm, Cambrex Corporation, Patheon (Thermo Fisher Scientific), CordenPharma, Lonza, Siegfried, Catalent, Boehringer Ingelheim, Piramal Group, AbbVie, SGS Quay Pharmaceuticals, Aenova Group, Curia, Sterling Pharma Solutions, Eurofins CDMO

What are the Application segmentation covered in the Active Pharmaceutical Ingredients (API) CDMO Market report?

Ans: The Applications covered in the Active Pharmaceutical Ingredients (API) CDMO Market report are Clinical, Commercial, Others

What are the Type segmentation covered in the Active Pharmaceutical Ingredients (API) CDMO Market report?

Ans: The Types covered in the Active Pharmaceutical Ingredients (API) CDMO Market report are Macromolecular API, Small Molecule API

Recommended Reports

API Market Segments

CDMO Industry Trends

Specialty APIs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Macromolecular API
1.2.3 Small Molecule API
1.3 Market by Application
1.3.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Clinical
1.3.3 Commercial
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Perspective (2020-2031)
2.2 Global Active Pharmaceutical Ingredients (API) CDMO Growth Trends by Region
2.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Region (2020-2025)
2.2.3 Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Region (2026-2031)
2.3 Active Pharmaceutical Ingredients (API) CDMO Market Dynamics
2.3.1 Active Pharmaceutical Ingredients (API) CDMO Industry Trends
2.3.2 Active Pharmaceutical Ingredients (API) CDMO Market Drivers
2.3.3 Active Pharmaceutical Ingredients (API) CDMO Market Challenges
2.3.4 Active Pharmaceutical Ingredients (API) CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue
3.1.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue (2020-2025)
3.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Active Pharmaceutical Ingredients (API) CDMO Revenue
3.4 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio
3.4.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2024
3.5 Global Key Players of Active Pharmaceutical Ingredients (API) CDMO Head office and Area Served
3.6 Global Key Players of Active Pharmaceutical Ingredients (API) CDMO, Product and Application
3.7 Global Key Players of Active Pharmaceutical Ingredients (API) CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Type
4.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Type (2020-2025)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Type (2026-2031)
5 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Application
5.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Application (2020-2025)
5.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
6.2 North America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
6.4 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
7.4 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
8.2 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
9.2 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
9.4 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size (2020-2031)
10.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm
11.1.1 Recipharm Company Details
11.1.2 Recipharm Business Overview
11.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Introduction
11.1.4 Recipharm Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.1.5 Recipharm Recent Development
11.2 Cambrex Corporation
11.2.1 Cambrex Corporation Company Details
11.2.2 Cambrex Corporation Business Overview
11.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Introduction
11.2.4 Cambrex Corporation Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.2.5 Cambrex Corporation Recent Development
11.3 Patheon (Thermo Fisher Scientific)
11.3.1 Patheon (Thermo Fisher Scientific) Company Details
11.3.2 Patheon (Thermo Fisher Scientific) Business Overview
11.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Introduction
11.3.4 Patheon (Thermo Fisher Scientific) Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.3.5 Patheon (Thermo Fisher Scientific) Recent Development
11.4 CordenPharma
11.4.1 CordenPharma Company Details
11.4.2 CordenPharma Business Overview
11.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Introduction
11.4.4 CordenPharma Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.4.5 CordenPharma Recent Development
11.5 Lonza
11.5.1 Lonza Company Details
11.5.2 Lonza Business Overview
11.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Introduction
11.5.4 Lonza Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.5.5 Lonza Recent Development
11.6 Siegfried
11.6.1 Siegfried Company Details
11.6.2 Siegfried Business Overview
11.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Introduction
11.6.4 Siegfried Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.6.5 Siegfried Recent Development
11.7 Catalent
11.7.1 Catalent Company Details
11.7.2 Catalent Business Overview
11.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Introduction
11.7.4 Catalent Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.7.5 Catalent Recent Development
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Details
11.8.2 Boehringer Ingelheim Business Overview
11.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Introduction
11.8.4 Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.8.5 Boehringer Ingelheim Recent Development
11.9 Piramal Group
11.9.1 Piramal Group Company Details
11.9.2 Piramal Group Business Overview
11.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.9.4 Piramal Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.9.5 Piramal Group Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Details
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Introduction
11.10.4 AbbVie Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.10.5 AbbVie Recent Development
11.11 SGS Quay Pharmaceuticals
11.11.1 SGS Quay Pharmaceuticals Company Details
11.11.2 SGS Quay Pharmaceuticals Business Overview
11.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Introduction
11.11.4 SGS Quay Pharmaceuticals Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.11.5 SGS Quay Pharmaceuticals Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Details
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.12.4 Aenova Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.12.5 Aenova Group Recent Development
11.13 Curia
11.13.1 Curia Company Details
11.13.2 Curia Business Overview
11.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Introduction
11.13.4 Curia Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.13.5 Curia Recent Development
11.14 Sterling Pharma Solutions
11.14.1 Sterling Pharma Solutions Company Details
11.14.2 Sterling Pharma Solutions Business Overview
11.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Introduction
11.14.4 Sterling Pharma Solutions Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.14.5 Sterling Pharma Solutions Recent Development
11.15 Eurofins CDMO
11.15.1 Eurofins CDMO Company Details
11.15.2 Eurofins CDMO Business Overview
11.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Introduction
11.15.4 Eurofins CDMO Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
11.15.5 Eurofins CDMO Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
List of Tables
 Table 1. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Macromolecular API
 Table 3. Key Players of Small Molecule API
 Table 4. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Region (2020-2025)
 Table 8. Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Region (2026-2031)
 Table 10. Active Pharmaceutical Ingredients (API) CDMO Market Trends
 Table 11. Active Pharmaceutical Ingredients (API) CDMO Market Drivers
 Table 12. Active Pharmaceutical Ingredients (API) CDMO Market Challenges
 Table 13. Active Pharmaceutical Ingredients (API) CDMO Market Restraints
 Table 14. Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Players (2020-2025)
 Table 16. Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2024)
 Table 17. Ranking of Global Top Active Pharmaceutical Ingredients (API) CDMO Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Active Pharmaceutical Ingredients (API) CDMO Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Active Pharmaceutical Ingredients (API) CDMO, Headquarters and Area Served
 Table 20. Global Key Players of Active Pharmaceutical Ingredients (API) CDMO, Product and Application
 Table 21. Global Key Players of Active Pharmaceutical Ingredients (API) CDMO, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Type (2020-2025)
 Table 25. Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Type (2026-2031)
 Table 27. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Application (2020-2025)
 Table 29. Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Application (2026-2031)
 Table 31. North America Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Recipharm Company Details
 Table 47. Recipharm Business Overview
 Table 48. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product
 Table 49. Recipharm Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 50. Recipharm Recent Development
 Table 51. Cambrex Corporation Company Details
 Table 52. Cambrex Corporation Business Overview
 Table 53. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product
 Table 54. Cambrex Corporation Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 55. Cambrex Corporation Recent Development
 Table 56. Patheon (Thermo Fisher Scientific) Company Details
 Table 57. Patheon (Thermo Fisher Scientific) Business Overview
 Table 58. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product
 Table 59. Patheon (Thermo Fisher Scientific) Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 60. Patheon (Thermo Fisher Scientific) Recent Development
 Table 61. CordenPharma Company Details
 Table 62. CordenPharma Business Overview
 Table 63. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product
 Table 64. CordenPharma Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 65. CordenPharma Recent Development
 Table 66. Lonza Company Details
 Table 67. Lonza Business Overview
 Table 68. Lonza Active Pharmaceutical Ingredients (API) CDMO Product
 Table 69. Lonza Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 70. Lonza Recent Development
 Table 71. Siegfried Company Details
 Table 72. Siegfried Business Overview
 Table 73. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product
 Table 74. Siegfried Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 75. Siegfried Recent Development
 Table 76. Catalent Company Details
 Table 77. Catalent Business Overview
 Table 78. Catalent Active Pharmaceutical Ingredients (API) CDMO Product
 Table 79. Catalent Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 80. Catalent Recent Development
 Table 81. Boehringer Ingelheim Company Details
 Table 82. Boehringer Ingelheim Business Overview
 Table 83. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product
 Table 84. Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 85. Boehringer Ingelheim Recent Development
 Table 86. Piramal Group Company Details
 Table 87. Piramal Group Business Overview
 Table 88. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product
 Table 89. Piramal Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 90. Piramal Group Recent Development
 Table 91. AbbVie Company Details
 Table 92. AbbVie Business Overview
 Table 93. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product
 Table 94. AbbVie Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 95. AbbVie Recent Development
 Table 96. SGS Quay Pharmaceuticals Company Details
 Table 97. SGS Quay Pharmaceuticals Business Overview
 Table 98. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product
 Table 99. SGS Quay Pharmaceuticals Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 100. SGS Quay Pharmaceuticals Recent Development
 Table 101. Aenova Group Company Details
 Table 102. Aenova Group Business Overview
 Table 103. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product
 Table 104. Aenova Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 105. Aenova Group Recent Development
 Table 106. Curia Company Details
 Table 107. Curia Business Overview
 Table 108. Curia Active Pharmaceutical Ingredients (API) CDMO Product
 Table 109. Curia Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 110. Curia Recent Development
 Table 111. Sterling Pharma Solutions Company Details
 Table 112. Sterling Pharma Solutions Business Overview
 Table 113. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product
 Table 114. Sterling Pharma Solutions Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 115. Sterling Pharma Solutions Recent Development
 Table 116. Eurofins CDMO Company Details
 Table 117. Eurofins CDMO Business Overview
 Table 118. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product
 Table 119. Eurofins CDMO Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025) & (US$ Million)
 Table 120. Eurofins CDMO Recent Development
 Table 121. Research Programs/Design for This Report
 Table 122. Key Data Information from Secondary Sources
 Table 123. Key Data Information from Primary Sources
 Table 124. Authors List of This Report


List of Figures
 Figure 1. Active Pharmaceutical Ingredients (API) CDMO Picture
 Figure 2. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Type: 2024 VS 2031
 Figure 4. Macromolecular API Features
 Figure 5. Small Molecule API Features
 Figure 6. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application: 2024 VS 2031
 Figure 8. Clinical Case Studies
 Figure 9. Commercial Case Studies
 Figure 10. Others Case Studies
 Figure 11. Active Pharmaceutical Ingredients (API) CDMO Report Years Considered
 Figure 12. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Active Pharmaceutical Ingredients (API) CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Region: 2024 VS 2031
 Figure 15. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Players in 2024
 Figure 16. Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2024
 Figure 18. North America Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2020-2031)
 Figure 20. United States Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2020-2031)
 Figure 24. Germany Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Share by Region (2020-2031)
 Figure 32. China Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2020-2031)
 Figure 40. Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2020-2031)
 Figure 44. Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Recipharm Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 48. Cambrex Corporation Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 49. Patheon (Thermo Fisher Scientific) Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 50. CordenPharma Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 51. Lonza Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 52. Siegfried Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 53. Catalent Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 54. Boehringer Ingelheim Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 55. Piramal Group Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 56. AbbVie Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 57. SGS Quay Pharmaceuticals Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 58. Aenova Group Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 59. Curia Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 60. Sterling Pharma Solutions Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 61. Eurofins CDMO Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2020-2025)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Active Pharmaceutical Ingredients CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmaceutical CMO and CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pharmaceutical CDMO Market Research Report 2025
Global Peptide API CDMO Services Market Research Report 2025
Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025
Pharmaceutical CDMO Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Active Pharmaceutical Ingredient API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Contract Dose Manufacturing Market Insights Forecast to 2030
Global Biopharmaceutical CDMO Market Research Report 2025
Global Chemical Drug CDMO Market Research Report 2024
Global Biopharmaceutical and Bio CDMO Market Research Report 2024
Global Biopharmaceutical CDMO Service Market Research Report 2024
Global Full Service CDMO Market Research Report 2024
Global Chemical CDMO Market Research Report 2024
Global Sterile Injectable CDMO Market Research Report 2024
Global Formulation CDMO Services Market Research Report 2024
Global Large Molecule Drug Substance CDMO Market Research Report 2024
Veterinary Active Pharmaceutical Ingredients API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmaceutical CDMO Services Market

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions